FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as asthma treatment guidelines.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Ild
Related signal: Study on Buteyko Breathing Technique's Impact on Childhood Asthma Control